Company

TILT Biotherapeutics Oy

TILT Biotherapeutics Oy, based in Helsinki, develops immunotherapies for solid tumors, focusing on platinum-resistant ovarian cancer.

About

Founded in 2013 in Helsinki, Finland, TILT Biotherapeutics Oy has completed 9 deals and is led by CEO Akseli Hemminki. Its lead product, TILT-123, is an oncolytic adenovirus in Phase I/II trials for platinum-resistant ovarian cancer. In May 2025 the company raised USD 25.6 mn in Series B funding led by European Innovation Council, Lifeline Ventures, Tesi and Stephen Industries, to advance the Phase 2 trial.

3Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in